How to launch a UK heavy menstrual bleeding telehealth service in 2026: the treatment ladder and the line into secondary care

Heavy menstrual bleeding is common, under-discussed, and mostly manageable without a hospital visit, which makes it look like an obvious telehealth fit. It is, up to a point. The medical options a prescriber can reach for remotely (tranexamic acid, NSAIDs, hormonal contraception, cyclical progestogens) cover a real share of cases. But NICE's own first-line recommendation for women who want ongoing treatment, the hormonal coil, needs hands-on fitting, and a meaningful minority of presentations are red flags in disguise. Building this vertical well means being precise about where the remote remit actually ends.

What counts as heavy menstrual bleeding in a telehealth remit

Heavy menstrual bleeding (sometimes still called menorrhagia) is defined less by a measured blood volume and more by impact: bleeding that disrupts a woman's physical, social, emotional or material quality of life, over one or more cycles. That subjective framing suits a remote consultation reasonably well, because the deciding factor is the patient's own account, not a clinical measurement a camera could capture anyway.

The telehealth-appropriate group is women with no suspected underlying structural or systemic cause: no fibroids large enough to cause pressure symptoms, no suspected polyps, no coagulation disorder, no recent significant change in bleeding pattern that points to something new. For everyone else, remote care is the triage step, not the treatment, and the wider women's health vertical needs a clear route out of it.

Diagnosis and triage without an examination or a scan

A remote consultation can take a thorough history: cycle length and regularity, pad or tampon use as a proxy for volume, clots, flooding, impact on work or daily life, associated pain, and any intermenstrual or postcoital bleeding. It cannot perform a pelvic examination, a transvaginal ultrasound, or a hysteroscopy, and none of those should be faked with a confident-sounding question set.

The practical workaround most services use is a structured triage questionnaire that flags anything outside the straightforward pattern, before a clinician ever makes a prescribing decision. Anaemia is the other thing to actively ask about: fatigue, breathlessness or dizziness alongside heavy bleeding is reasonable grounds to request a blood test through the wider service rather than prescribing blind.

The treatment ladder: what a remote prescriber can actually offer

For women with no identified structural cause, several options sit comfortably within a telehealth remit, all of them prescription-only medicines:

• Tranexamic acid, an antifibrinolytic taken only during the bleeding days, often the first call for women who don't need contraception
• Mefenamic acid or another NSAID, useful where pain accompanies the bleeding, taken with the same caveats as any NSAID around gastrointestinal and renal history
• Combined hormonal contraception, where contraception is also wanted and there's no contraindication such as migraine with aura or a personal history of venous thromboembolism
• Cyclical oral progestogens, typically reserved for women who need rapid short-term control

Each of these can be prescribed after a careful history and standard contraindication screening, which is the same clinical workflow the PCOS pathway already needs for its own hormonal options.

The coil problem: why the first-line option sits outside remote care

NICE's guidance names the levonorgestrel intrauterine system (LNG-IUS, branded as Mirena among others) as the option to offer first when a woman has no identified pathology, doesn't need or want to try medical treatment first, and is likely to want contraception for longer than a year. In plain terms, it's often the single most effective non-surgical option, and in a lot of cases it's the NICE-preferred one.

It also cannot be fitted remotely. A telehealth service can discuss it, explain why it might suit a particular patient, and refer her into an in-person fitting service, whether that's the service's own affiliated clinic network or an NHS or private alternative. What it cannot do is let a video consultation substitute for the procedure itself, and a service that implies otherwise is setting up a complaint.

The referral line: symptoms that are not a telehealth prescribing decision

Some presentations should stop a remote consultation from becoming a prescription at all. Postmenopausal bleeding is the clearest one: any bleeding after the menopause needs urgent in-person assessment to rule out endometrial cancer, not a telehealth medicine. Intermenstrual bleeding, postcoital bleeding, and persistent pelvic pain alongside heavy bleeding all point toward a possible structural or gynaecological cause that needs examination or imaging before treatment, not after it.

A sudden, marked change in a previously stable bleeding pattern deserves the same caution, as does bleeding heavy enough to cause the signs of significant blood loss. The role of a well-built service here is recognising its own limits quickly and routing the patient to in-person care, rather than trying to manage every case that walks in the door.

A telehealth service that can prescribe five medicines but recognise zero red flags is not a safer version of in-person care, it is a slower way to miss the same thing a GP would have caught in the room.

Building the pathway: consent, documentation and safety-netting

A defensible heavy menstrual bleeding pathway documents the triage questions asked, the specific contraindications screened, and the reason a particular medicine was chosen over the alternatives. It also builds in a review point, typically a few cycles after starting treatment, to check whether the bleeding has actually improved rather than assuming a prescription once was a prescription forever.

Safety-netting advice matters as much as the medicine: what to do, and how urgently, if bleeding gets heavier rather than lighter, if new symptoms appear, or if the red flags above show up after treatment has started. Clear written advice at the point of prescribing reduces both clinical risk and the number of confused patients contacting support days later.

Where PExpo fits

A heavy menstrual bleeding vertical needs the same regulated backbone as any other prescribing pathway: a superintendent pharmacist accountable for dispensing decisions, a dispensing operation that can fulfil tranexamic acid, NSAIDs and hormonal medicines reliably, and clinical governance that supports prescribers in recognising when a case needs to leave the remote pathway rather than stay in it.

PExpo's white-label dispensing and clinic infrastructure gives brands and clinics that groundwork without each one building it from scratch, whether the service sits under a brand's own front end or runs through a clinic's existing patient base. The clinical judgement about where a case belongs still sits with the prescriber; the infrastructure around it is what makes that judgement safe to act on at scale.

Heavy menstrual bleeding is a genuine telehealth opportunity, not a full substitute for in-person gynaecology. The medicines that travel well remotely (tranexamic acid, NSAIDs, hormonal contraception, cyclical progestogens) cover real demand; the coil and the red-flag presentations are the honest boundary. Services that build that boundary into their triage from day one, rather than discovering it through a complaint, are the ones that last. See how this fits alongside other UK women's health verticals or explore white-label platform options for launching it.

Frequently asked questions